Tags

Type your tag names separated by a space and hit enter

Bisphosphonates in the treatment of metabolic bone diseases.
Ann Med. 1993 Aug; 25(4):373-8.AM

Abstract

Bisphosphonates (BP) are pyrophosphate analogs, P-C-P with various carbon side-chains. The phosphate groups are responsible for the low gastrointestinal absorption (about 1%), limited penetration into cells, adsorption to bone mineral and rapid excretion in the urine. Based on the C side-chains, BPs can inhibit osteoclastic bone resorption with potencies which differ by as much as 10,000-fold among compounds. The most potent inhibitors are aminobisphosphonates. Studies of the amino-BP alendronate show preferential uptake at sites of bone resorption where they block osteoclastic activity by inhibiting ruffled border formation. BPs are the treatment of choice for hypercalcaemia of malignancy, where a single infusion with a potent BP will normalize serum calcium in 80% of the patients. Paget's disease also shows an excellent long-term response to BPs. In addition, BPs are being studied for the treatment of osteoporosis and other bone disorders which could be helped by inhibition of bone resorption.

Authors+Show Affiliations

Department of Bone Biology and Osteoporosis Research, Merck Sharp and Dohme Research Laboratories, West Point, PA 19486.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8217103

Citation

Rodan, G A., and R Balena. "Bisphosphonates in the Treatment of Metabolic Bone Diseases." Annals of Medicine, vol. 25, no. 4, 1993, pp. 373-8.
Rodan GA, Balena R. Bisphosphonates in the treatment of metabolic bone diseases. Ann Med. 1993;25(4):373-8.
Rodan, G. A., & Balena, R. (1993). Bisphosphonates in the treatment of metabolic bone diseases. Annals of Medicine, 25(4), 373-8.
Rodan GA, Balena R. Bisphosphonates in the Treatment of Metabolic Bone Diseases. Ann Med. 1993;25(4):373-8. PubMed PMID: 8217103.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bisphosphonates in the treatment of metabolic bone diseases. AU - Rodan,G A, AU - Balena,R, PY - 1993/8/1/pubmed PY - 1993/8/1/medline PY - 1993/8/1/entrez SP - 373 EP - 8 JF - Annals of medicine JO - Ann Med VL - 25 IS - 4 N2 - Bisphosphonates (BP) are pyrophosphate analogs, P-C-P with various carbon side-chains. The phosphate groups are responsible for the low gastrointestinal absorption (about 1%), limited penetration into cells, adsorption to bone mineral and rapid excretion in the urine. Based on the C side-chains, BPs can inhibit osteoclastic bone resorption with potencies which differ by as much as 10,000-fold among compounds. The most potent inhibitors are aminobisphosphonates. Studies of the amino-BP alendronate show preferential uptake at sites of bone resorption where they block osteoclastic activity by inhibiting ruffled border formation. BPs are the treatment of choice for hypercalcaemia of malignancy, where a single infusion with a potent BP will normalize serum calcium in 80% of the patients. Paget's disease also shows an excellent long-term response to BPs. In addition, BPs are being studied for the treatment of osteoporosis and other bone disorders which could be helped by inhibition of bone resorption. SN - 0785-3890 UR - https://www.unboundmedicine.com/medline/citation/8217103/Bisphosphonates_in_the_treatment_of_metabolic_bone_diseases_ L2 - https://www.tandfonline.com/doi/full/10.3109/07853899309147299 DB - PRIME DP - Unbound Medicine ER -